Cardiology

Higher risks without cardio benefits halt study of aleglitazar

The phase III AleCardio trial was ended early when patients with type 2 diabetes and recent acute coronary syndrome who were treated with aleglitazar showed higher rates of heart failure, kidney events and gastrointestinal ...

Cardiology

Newer anticoagulants linked to gastrointestinal bleeding

(HealthDay)—Patients taking the new generation of oral anticoagulants appear to have a higher risk of gastrointestinal bleeding compared with standard care, particularly when treated for venous thrombosis or acute coronary ...

page 6 from 10